Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.47 |
| ▸ | CES1 | P23141 | 6/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670577 | 1.00 | CES2 (0.47) | CES2CES1HDAC1HDAC6KEAP1 | |
| SCHEMBL20670887 | 0.83 | KDM4E (0.47) | HDAC1HDAC6SMN1; SMN2TSHRALOX5AP | |
| SCHEMBL29467960 | 0.82 | KDM4E (0.46) | CES2CES1KEAP1SMN1; SMN2TSHR | |
| SCHEMBL2060245 | 0.81 | KEAP1 (0.53) | CES2CES1HDAC1HDAC6KEAP1 | |
| SCHEMBL2308943 | 0.81 | CES2 (0.48) | CES2CES1HDAC1HDAC6KEAP1 | |
| SCHEMBL20670574 | 0.80 | CYP3A4 (0.40) | HDAC1HDAC6MAOBALOX5APFEN1 | |
| SCHEMBL4092168 | 0.80 | DGAT1 (0.43) | HDAC1HDAC6MAOBSMN1; SMN2TSHR | |
| SCHEMBL10595723 | 0.80 | GSK3B (0.36) | CES2CES1HDAC1HDAC6KEAP1 | |
| SCHEMBL2719368 | 0.80 | KEAP1 (0.36) | CES2CES1KEAP1 | |
| SCHEMBL4605786 | 0.80 | HDAC1 (0.36) | HDAC1HDAC6MAOBSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4141001-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2024-10-17 | — | — | US | disclosed |
| CN-110914262-B | Kappa opioid receptor antagonists and products and methods relating thereto | 斯克里普斯研究所 | 2024-04-05 | — | — | CN | disclosed |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4141001-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3596069-B1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | SCRIPPS RESEARCH INST (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162202-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | CES2 2736/4885CES1 1363/4885HDAC1 992/4885 |
| US-20240343719-A1 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | OPRK1, OPRD1, OPRM1 | CES2 2633/4885CES1 1322/4885HDAC1 993/4885 |
| US-11897873-B2 | Kappa opioid receptor antagonists and products and methods related thereto | OPRK1, OPRD1, OPRM1 | CES2 2673/4885CES1 1320/4885HDAC1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.